Correlation analysis of Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B patients
Th1/Th2 cytokines and liver fibrosis indicators in chronic hepatitis B
Abstract
Objective: To investigate the potential therapeutic benefits of autoimmune antibody detection in individuals suffering from chronic hepatitis B. Methods: For the observation group, 102 patients with chronic hepatitis B who were admitted between March 2022 and March 2025 were chosen. Additionally, the control group consisted of 102 healthy people who were examined throughout the same time period. The two groups' autoimmune antibodies were identified, and patients in the observation group with positive and negative autoimmune antibodies were compared in terms of their liver function, liver fibrosis markers, and cytokine levels. Results: The total positive rate of autoimmune antibodies in the observation group was 26.47%, whereas it was 3.92% in the control group (P<0.05). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were noticeably greater in the observation group's patients with positive autoimmune antibodies than in those with negative antibodies. However, the albumin (ALB) and total protein (TP) levels were much lower than those of patients with negative antibodies. A statistically significant difference was observed (P<0.05). Type III procollagen (PCIII), hyaluronidase (HA), and the levels of laminin (LN) were statistically significant (P<0.05) higher in individuals with positive autoimmune antibodies than in those with negative antibodies. Patients with positive autoimmune antibodies had considerably higher levels of interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-6 (IL-6) than patients with negative antibodies. Patients with negative antibodies had significantly higher levels of interferon-γ (IFN-γ) (P < 0.05). Conclusion: Autoimmune antibodies are present in patients with chronic hepatitis B, which influence liver fibrosis indicators and related cytokines. The identification of autoimmune antibodies in chronic hepatitis B patients can serve as a guide for evaluating the illness and determining prognosis.
References
2.Shen Y, Wu SD, Chen Y, Li XY, Zhu Q, Nakayama K, Zhang WQ, Weng CZ, Zhang J, Wang HK, Wu J, Jiang W. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes. 2023 Jan-Dec;15(1):2155018. doi: 10.1080/19490976.2022.2155018. PMID: 36519342; PMCID: PMC9757487.
3.Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, Han NX, Fong KY, Chen E, Wong C, Rui F, Xu X, Xue Q, Hu XY, Leow WQ, Goh GB, Cheung R, Wong G, Wong VW, Yu MW, Nguyen MH. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023 Jul;29(3):705-720. doi: 10.3350/cmh.2023.0004. Epub 2023 May 8. PMID: 37157776; PMCID: PMC10366810.
4.Rui F, Xu L, Yeo YH, Xu Y, Ni W, Tan Y, Zheng Q, Tian X, Zeng QL, He Z, Qiu Y, Zhu C, Ding W, Wang J, Huang R, Xue Q, Wang X, Chen Y, Fan J, Fan Z, Ogawa E, Kwak MS, Qi X, Shi J, Wong VW, Wu C, Li J. Machine Learning-Based Models for Advanced Fibrosis and Cirrhosis Diagnosis in Chronic Hepatitis B Patients With Hepatic Steatosis. Clin Gastroenterol Hepatol. 2024 Nov;22(11):2250-2260.e12. doi: 10.1016/j.cgh.2024.06.014. Epub 2024 Jun 19. PMID: 38906440.
5.Huang SC, Kao JH. Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. J Formos Med Assoc. 2022 Nov;121(11):2148-2151. doi: 10.1016/j.jfma.2022.07.013. Epub 2022 Aug 15. PMID: 35981929.
6.Sheng R, Zhang Y, Sun W, Ji Y, Zeng M, Yao X, Dai Y. Staging Chronic Hepatitis B Related Liver Fibrosis with a Fractional Order Calculus Diffusion Model. Acad Radiol. 2022 Jul;29(7):951-963. doi: 10.1016/j.acra.2021.07.005. Epub 2021 Aug 22. PMID: 34429260.
7.Jiang T, Leng W, Zhong S. Diagnostic Role of Circulating miRNAs in the Grading of Chronic Hepatitis B-Related Liver Fibrosis: A Systematic Review and Meta-Analysis. Lab Med. 2023 Sep 5;54(5):479-488. doi: 10.1093/labmed/lmac151. PMID: 36637253.
8.Stalla F, Armandi A, Marinoni C, Fagoonee S, Pellicano R, Caviglia GP. Chronic hepatitis B virus infection and fibrosis: novel noninvasive approaches for diagnosis and risk stratification. Minerva Gastroenterol (Torino). 2022 Sep;68(3):306-318. doi: 10.23736/S2724-5985.21.02911-9. Epub 2021 Apr 19. PMID: 33871225.
9.Meng X, Pan Z, Zhao J, Feng Q. Efficacy and safety of Fufang Biejia Ruangan Tablets as an adjuvant treatment for chronic hepatitis B liver fibrosis: A systematic review and meta-analysis. Medicine (Baltimore). 2022 Nov 18;101(46):e31664. doi: 10.1097/MD.0000000000031664. PMID: 36401442; PMCID: PMC9678545.
10.Liguori A, Zoncapè M, Casazza G, Easterbrook P, Tsochatzis EA. Staging liver fibrosis and cirrhosis using noninvasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 Apr;10(4):332-349. doi: 10.1016/S2468-1253(24)00437-0. Epub 2025 Feb 18. PMID: 39983746.
11.Lin MH, Li HQ, Zhu L, Su HY, Peng LS, Wang CY, He CP, Liang XE, Wang Y. Liver Fibrosis in the Natural Course of Chronic Hepatitis B Viral Infection: A Systematic Review with Meta-Analysis. Dig Dis Sci. 2022 Jun;67(6):2608-2626. doi: 10.1007/s10620-021-07009-y. Epub 2021 May 18. PMID: 34008117.
12.Chen N, Sun Y, Luo P, Tang Y, Fan Y, Han L, Wang K. Association of CXCR4 gene expression and promoter methylation with chronic hepatitis B-related fibrosis/cirrhosis. Int Immunopharmacol. 2024 Sep 30;139:112686. doi: 10.1016/j.intimp.2024.112686. Epub 2024 Jul 25. PMID: 39053226.
13.Kim GA, Choi SW, Han S, Lim YS. Nonlinear association between liver fibrosis scores and viral load in patients with chronic hepatitis B. Clin Mol Hepatol. 2024 Oct;30(4):793-806. doi: 10.3350/cmh.2024.0252. Epub 2024 Jul 19. PMID: 39026397; PMCID: PMC11540400.
14.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
15.Fan R, Li G, Yu N, Chang X, Arshad T, Liu WY, Chen Y, Wong GL, Jiang Y, Liang X, Chen Y, Jin XZ, Dong Z, Leung HH, Wang XD, Zeng Z, Yip TC, Xie Q, Tan D, You S, Ji D, Zhao J, Sanyal AJ, Sun J, Zheng MH, Wong VW, Yang Y, Hou J. aMAP Score and Its Combination With Liver Stiffness Measurement Accurately Assess Liver Fibrosis in Chronic Hepatitis B Patients. Clin Gastroenterol Hepatol. 2023 Nov;21(12):3070-3079.e13. doi: 10.1016/j.cgh.2023.03.005. Epub 2023 Mar 17. PMID: 36933605.
16.Kavak S, Kaya S, Senol A, Sogutcu N. Evaluation of liver fibrosis in chronic hepatitis B patients with 2D shear wave elastography with propagation map guidance: a single-center study. BMC Med Imaging. 2022 Mar 18;22(1):50. doi: 10.1186/s12880-022-00777-7. PMID: 35303822; PMCID: PMC8932279.
17.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
18.Cai X, Liu X, Xie W, Ma A, Tan Y, Shang J, Zhang J, Chen C, Yu Y, Qu Y, Zhang L, Luo Y, Yin P, Cheng J, Lu L. Hydronidone for the Treatment of Liver Fibrosis Related to Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1893-1901.e7. doi: 10.1016/j.cgh.2022.05.056. Epub 2022 Jul 13. PMID: 35842120.
19.Jiang C, Liu J, Li R, Chen K, Peng W, Fu L, Peng S. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 May 28;48(5):698-706. English, Chinese. doi: 10.11817/j.issn.1672-7347.2023.220622. PMID: 37539572; PMCID: PMC10930400.
20.Dilcan KH, Gozdas HT. Noninvasive evaluation of significant liver fibrosis in chronic hepatitis B patients. Acta Gastroenterol Belg. 2024 Jul-Sep;87(3):388-392. doi: 10.51821/87.3.13290. PMID: 39411792.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
21.Wang WM, Zhang WS, Yang ZG. Vimentin (VIM) predicts advanced liver fibrosis in chronic hepatitis B patients: A random forest-derived analysis. Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):5164-5177. doi: 10.26355/eurrev_202207_29305. PMID: 35916814.
22.Wang WM, Zhang WS, Yang ZG. Vimentin (VIM) predicts advanced liver fibrosis in chronic hepatitis B patients: A random forest-derived analysis. Eur Rev Med Pharmacol Sci. 2022 Jul;26(14):5164-5177. doi: 10.26355/eurrev_202207_29305. PMID: 35916814.
23.Zhang C, Liu Y, Wang L, Liu X, Chen C, Zhang J, Zhang C, Wang G, Zhuang H, Zhao H; China HepB-Related Fibrosis Assessment Research Group. Dose‒response relationship between serum N-glycan markers and liver fibrosis in chronic hepatitis B. Hepatol Int. 2024 Oct;18(5):1434-1447. doi: 10.1007/s12072-024-10709-y. Epub 2024 Jul 17. PMID: 39017915; PMCID: PMC11461603.
24.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
25.Pan Z, Li Z, Meng F, Hu Y, Zhang X, Chen Y. Fat- and iron-corrected ADC to assess liver fibrosis in patients with chronic hepatitis B. Diagn Interv Radiol. 2022 Jan;28(1):5-11. doi: 10.5152/dir.2021.21471. PMID: 34914604; PMCID: PMC12278920.
26.Luu NM, Nguyen TKT, Vu TT, Dinh TS, Luu NH, Do TTT, Nguyen VS, Ha TBV, Nguyen DC, Tran TH, Phung TTH, Duong XP, Khuong QL, Nguyen TTT, Saw YM, Hoang TNA, Nguyen TN. Progression of liver fibrosis and associated factors among chronic hepatitis B patients at a general hospital in Northern Vietnam. Nagoya J Med Sci. 2022 Feb;84(1):19-28. doi: 10.18999/nagjms.84.1.19. PMID: 35392005; PMCID: PMC8971045.
27.Bui HH, Nguyen ST, Phan ST, Nguyen KM, Nguyen CD. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B. Dig Dis Sci. 2023 Dec;68(12):4407-4417. doi: 10.1007/s10620-023-08143-5. Epub 2023 Oct 20. PMID: 37861877; PMCID: PMC10635958.
28.Tan Y, Zhang X. Diagnostic accuracy of FibroScan-AST (FAST) score, nonalcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic nonalcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease. Ann Med. 2024 Dec;56(1):2420858. doi: 10.1080/07853890.2024.2420858. Epub 2024 Oct 26. PMID: 39460547; PMCID: PMC11514388.
29.Yang K, Pan Y, Liu L, Sun B, Shi W. Serum Alpha-Fetoprotein as a Predictor of Liver Fibrosis in HBeAg-Positive Chronic Hepatitis B Patients. Medicina (Kaunas). 2023 May 11;59(5):923. doi: 10.3390/medicina59050923. PMID: 37241155; PMCID: PMC10221886.
30.Saab S, Pham N, Wu W, Dang L, Dang A, Yum J, Shim K, Wu S. Spontaneous Seroclearance Is Associated with Lower Liver Fibrosis in Treatment-Naïve Chronic Hepatitis B Patients. Dig Dis Sci. 2022 Nov;67(11):5309-5314. doi: 10.1007/s10620-022-07402-1. Epub 2022 Mar 4. PMID: 35244827.
31.Sohn W, Chang Y, Cho YK, Hong YS, Shin H, Ryu S. Liver fibrosis scores and risk of liver-related mortality in young adults with chronic hepatitis B: A cohort study. J Viral Hepat. 2022 Jan;29(1):69-77. doi: 10.1111/jvh.13618. Epub 2021 Oct 7. PMID: 34582599.
32.Zhang X, Wan Z, Lin M, Li Y, Wu X, Jiang J, Lin S, Chi X. Immunoglobulin A and complement C4 are involved in the progression of liver fibrosis in patients with chronic hepatitis B. Int Immunopharmacol. 2023 Sep;122:110604. doi: 10.1016/j.intimp.2023.110604. Epub 2023 Jul 12. PMID: 37451022.
33.Chen N, Luo P, Tang Y, Liu P, Wang J, Fan Y, Han L, Wang K. Accelerators of chronic hepatitis B fibrosis cirrhosis CCND1 gene expression and promoter hypomethylation. Sci Rep. 2025 Mar 27;15(1):10630. doi: 10.1038/s41598-025-93778-9. PMID: 40148411; PMCID: PMC11950333.
34.Yang C, Geng H, Zhu S, Zheng X, Li T, Duan L. Multiple Diagnostic Indicators in the Development of Chronic Hepatitis B, Liver Cirrhosis, and Liver Cancer. Altern Ther Health Med. 2023 Apr;29(3):153-159. PMID: 36735716.
35.Sapmaz FP, Büyükturan G, Sakin YS, Kalkan İH, Atasoy P. How effective are APRI, FIB-4, FIB-5 scores in predicting liver fibrosis in chronic hepatitis B patients? Medicine (Baltimore). 2022 Sep 9;101(36):e30488. doi: 10.1097/MD.0000000000030488. PMID: 36086763; PMCID: PMC10980425.
36.Liu Z, Wen H, Zhu Z, Li Q, Liu L, Li T, Xu W, Hou C, Huang B, Li Z, Dong C, Chen X. Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network. Hepatol Int. 2022 Jun;16(3):526-536. doi: 10.1007/s12072-021-10294-4. Epub 2022 Mar 21. PMID: 35312969.
37.Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China. World J Gastroenterol. 2022 Jul 21;28(27):3503-3513. doi: 10.3748/wjg.v28.i27.3503. PMID: 36158257; PMCID: PMC9346453.
38.Ekmen MO, Uzman M. The Relationship between Mean Platelet Volume and Neutrophil-Lymphocyte Ratio and Liver Fibrosis in Patients with Chronic Hepatitis B. Medicina (Kaunas). 2023 Jul 12;59(7):1287. doi: 10.3390/medicina59071287. PMID: 37512098; PMCID: PMC10384412.
Copyright (c) 2025 Chun Yu, Meiling Chen, Xiaonan Han, Yuhang Feng, Hongwei Sun, Hong Yang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.